SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)

被引：0

作者：

Dimopoulos, M. ^{[1
]}

Trotman, J. ^{[2
]}

Tedeschi, A. ^{[3
]}

Matous, J. V. ^{[4
]}

Macdonald, D. ^{[5
]}

Tam, C. ^{[6
,7
]}

Tournilhac, O. ^{[8
]}

Ma, S. ^{[9
]}

Oriol, A. ^{[10
]}

Heffner, L. ^{[11
]}

Shustik, C. ^{[12
]}

Garcia-Sanz, R. ^{[13
]}

Cornell, R. F. ^{[14
]}

Fernandez de Larrea, C. ^{[15
]}

Castillo, J. J. ^{[16
]}

Granell, M. ^{[17
]}

Kyrtsonis, M. C. ^{[18
]}

Leblond, V. ^{[17
,19
]}

Symeonidis, A. ^{[20
]}

Singh, P. ^{[21
]}

Li, J. ^{[21
]}

Graef, T. ^{[21
]}

Bilotti, E. ^{[21
]}

Treon, S. ^{[16
]}

Buske, C. ^{[22
]}

机构：

[1] Univ Athens, Sch Med, Athens 11528, Greece

[2] Univ Sydney, Concord Hosp, Sydney, NSW 2006, Australia

[3] Osped Niguarda Ca Granda, Milan, Italy

[4] Colorado Blood Canc Inst, Denver, CO USA

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Peter MacCallum Canc Ctr, Melbourne, Australia

[7] St Vincents Hosp, Melbourne, Australia

[8] CHU Clermont Ferrand, Hematol Clin Adulte & Therapie Cellulaire, Clermont Ferrand, France

[9] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[10] Hosp Badalona Germans Trias & Pujol, Catala Oncol 9Inst, Barcelona, Spain

[11] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[12] McGill Univ Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada

[13] Hosp Univ Salamanca, Salamanca, Spain

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Hosp Sant Pau, Barcelona, Spain

[18] Univ Athens, Athens 11528, Greece

[19] UPMC Univ Paris, Hop Pitie Salpetriere APHP, Paris, France

[20] Univ Patras, Medial Sch, Patras, Greece

[21] AbbVie Co, Pharmacyclics LLC, Sunnyvale, CA USA

[22] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, INNOVATE TM Study Grp, Ulm, Germany

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P652

引用

页码：256 / 257

页数：2

共 50 条

[41] Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients
Kurihara, Yuichi
Yamagami, Jun
Funakoshi, Takeru
Ishii, Maki
Miyamoto, Julia
Fujio, Yumi
Kakuta, Risa
Tanikawa, Akiko
Aoyama, Yumi
Iwatsuki, Keiji
Ishii, Norito
Hashimoto, Takashi
Nishie, Wataru
Shimizu, Hiroshi
Kouyama, Keisuke
Amagai, Masayuki
JOURNAL OF DERMATOLOGY, 2019, 46 (02): : 124 - 130
[42] Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study
Gopal, Ajay K.
Schuster, Stephen J.
Fowler, Nathan
Trotman, Judith
Hess, Georg
Hou, Jing-Zhou
Yacoub, Abdulraheem
Lill, Michael
Martin, Peter
Vitolo, Umberto
Jurczak, Wojciech
Morton, James
Osmanov, Dzhelil
Gartenberg, Gary J.
Vermeulen, Jessica
Balasubramanian, Sriram
Wang, Shean-sheng
Deshpande, Sanjay
Salles, Gilles A.
BLOOD, 2016, 128 (22)
[43] Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
Siegel, David S.
Schiller, Gary J.
Samaras, Christy J.
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin W.
Seet, Christopher S.
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald P.
Anz, Bertrand M., III
Fonseca, Gustavo A.
Reece, Donna E.
Lee, Kim
Chung, Weiyuan
Agarwal, Amit
Bahlis, Nizar J.
BLOOD, 2020, 136
[44] A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Sia, Hanlon
Tan, Peter T.
Richter, Joshua
Ho, Phoebe Joy
Cochrane, Tara
Quach, Hang
Dhakal, Binod
Proscurshim, Igor
Jiang, Tony
Mancino, Emaryn
Salhi, Yacine
Stefano, Sammicheli
Gudi, Girish
Garton, Andrew
Feldman, Eric J.
Spencer, Andrew
BLOOD, 2022, 140 : 10182 - 10184
[45] Bendamustine HCI (TREANDA™) treatment results in high rates of objective response in patients with rituximab-refractory and alkylator-refractory indolent B-Cell non-hodgkin's lymphoma (NHL):: Results from a phase II multicenter single-agent study (SDX-105-01).
Friedberg, JW
Cohen, P
Cheson, BD
Robinson, KS
Forero-Torres, A
Fayad, L
La Casce, AS
Bessudo, A
Camacho, ES
Williams, ME
van der Jagt, RH
Oliver, J
Benaim, E
BLOOD, 2005, 106 (11) : 70A - 70A
[46] NURSING EXPERIENCE WITH PATIENTS RECEIVING IBRUTINIB PLUS RITUXIMAB VERSUS PLACEBO PLUS RITUXIMAB FOR WALDENSTROM'S MACROGLOBULINEMIA: FIVE YEARS OF FOLLOW-UP FROM THE PHASE 3 INNOVATE™ STUDY
Adewuya, Tolu
Mimken, Kate
Hauns, Bernhard
Arango-Hisijara, Israel
Matous, Jeffrey
Heffner, Leonard
ONCOLOGY NURSING FORUM, 2021, 48 (02)
[47] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
O'Brien, Maureen M.
Alonzo, Todd A.
Cooper, Todd M.
Levine, John E.
Brown, Patrick A.
Slone, Tamra
August, Keith J.
Benettaib, Bouchra
Biserna, Noha
Poon, Jennifer
Patturajan, Meera
Chen, Nianhang
Simcock, Mathew
Zimmerman, Linda
Kolb, E. Anders
PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
[48] An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Vij, Ravi
Siegel, David S.
Jagannath, Sundar
Jakubowiak, Andrzej J.
Stewart, Alexander Keith
McDonagh, Kevin
Bahlis, Nizar
Belch, Andrew
Kunkel, Lori A.
Wear, Sandra
Wong, Alvin F.
Orlowski, Robert Z.
Wang, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (06) : 739 - 748
[49] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors
Harrington, Kevin Joseph
Rullan, Antonio
Deighton, Louise
Barata, Joao
Castro, Henry
Ahlers, Christoph Matthias
Mcrae, John
Bommareddy, Praveen
Coffin, Robert S.
Middleton, Mark R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Sehn, Laurie H.
Chua, Neil
Mayer, Jiri
Dueck, Gregg
Trneny, Marek
Bouabdallah, Kamal
Fowler, Nathan
Delwail, Vincent
Press, Oliver
Salles, Gilles
Gribben, John
Lennard, Anne
Lugtenburg, Pieternella J.
Dimier, Natalie
Wassner-Fritsch, Elisabeth
Fingerle-Rowson, Guenter
Cheson, Bruce D.
LANCET ONCOLOGY, 2016, 17 (08): : 1081 - 1093

← 1 2 3 4 5 →